Share This Author
Trastuzumab emtansine (T-DM1) renders HER2+ breast cancer highly susceptible to CTLA-4/PD-1 blockade
- Philipp Müller, M. Kreuzaler, A. Zippelius
- Biology, MedicineScience Translational Medicine
- 25 November 2015
T-DM1 is particularly effective in eliciting antitumor immunity in patients with early breast cancer and in a HER2-expressing orthotopic tumor model, and it is shown that it can be used in combination therapy.
West German Study Group Phase III PlanB Trial: First Prospective Outcome Data for the 21-Gene Recurrence Score Assay and Concordance of Prognostic Markers by Central and Local Pathology Assessment.
The substantial discordance observed between traditional prognostic markers and RS emphasizes the need for standardized assessment and supports the potential integration of standardized, well-validated genomic assays such as RS with clinicopathologic prognostic factors for chemotherapy indication in early hormone receptor-positive breast cancer.
Standardized evaluation of tumor-infiltrating lymphocytes in breast cancer: results of the ring studies of the international immuno-oncology biomarker working group
This large international standardization project shows that reproducible evaluation of TIL is feasible in breast cancer and opens the way for standardized reporting of tumor immunological parameters in clinical studies and diagnostic practice.
Reducing chemotherapy use in clinically high-risk, genomically low-risk pN0 and pN1 early breast cancer patients: five-year data from the prospective, randomised phase 3 West German Study Group (WSG)…
Five-year outcomes in clinically high-risk, genomically low-risk pN0-1 patients without adjuvant chemotherapy support using RS with standardised pathology for treatment decisions in HR+ HER2-negative EBC has the potential to support patient selection for genomic testing.
MicroRNA profiles of healthy basal and luminal mammary epithelial cells are distinct and reflected in different breast cancer subtypes
- C. Bockmeyer, M. Christgen, U. Lehmann
- Biology, MedicineBreast Cancer Research and Treatment
- 17 March 2011
Both microRNAs were expressed in the luminal and basal type of breast cancer in contrast to malignant myoepithelioma, which revealed significantly lower levels potentially contributing to its mesenchymal phenotype.
High frequency of lobular breast cancer in distant metastases to the orbit
Lobular breast cancer represents the cancer subtype with the highest prevalence among orbital metastases and illustrates the special metastatic behavior of this tumor entity and may have implications for the understanding of the organotropism of metastatic lobular breastcancer.
Identification of a distinct side population of cancer cells in the Cal-51 human breast carcinoma cell line
- M. Christgen, M. Ballmaier, Henriette Bruchhardt, R. Wasielewski, H. Kreipe, U. Lehmann
- BiologyMolecular and Cellular Biochemistry
- 28 July 2007
Cal-51 SP cells are established as a novel in vitro model to study differential gene expression in breast cancer-derived SP and NSP cells and non-malignant mammary epithelial SP cells lack these differentiation markers.
Resistance of pancreatic cancer to gemcitabine treatment is dependent on mitochondria‐mediated apoptosis
A functional restoration of this pathway appears to be essential to overcome the resistance mechanisms of pancreatic tumor cells and to improve the response to therapy as demonstrated by Bax overexpression in a clinically relevant tumor model.
Manumycin enhances the cytotoxic effect of paclitaxel on anaplastic thyroid carcinoma cells.
Manumycin plus paclitaxel has enhanced cytotoxic effects and increased apoptotic cell death in ATC cells in vitro compared with either drug by itself and in vivo and is also effective in vivo with no significant toxicity observed.